🎯 Drug Targets

Upregulation through PCSK9 inhibition or direct receptor modulation

Agonist antibodies that enhance TREM2 signaling to promote microglial function

Monoclonal antibodies targeting receptor or iron chelation affecting iron uptake

Small molecule antagonist or antibody blocking TLR4-mediated neuroinflammatory signaling

Monoclonal antibodies targeting receptor or iron chelation affecting iron uptake

Modulation of receptor-mediated endocytosis and clearance pathways

Small molecule modulation of heparan sulfate interactions or shedding

Prioritized from 1 SciDEX hypotheses, including: Purinergic Signaling Polarization Control

Drugs targeting IGF2R typically work by blocking IGF2 binding and signaling through the IGF1R/IGF2R axis, thereby inhibiting mitogenic and anti-apoptotic effects in cancer cells. Alternatively, agents may enhance IGF2 clearance through IGF2R-mediated endocytosis to reduce circulating IGF2 levels and downstream signaling.

Drugs targeting NLGN1 would modulate synaptic adhesion by either enhancing or blocking the neuroligin-neurexin interaction at the postsynaptic membrane, thereby regulating synapse formation, stabilization, and synaptic transmission. Indirect modulators may enhance GABAergic signaling or vasopressin-mediated pathways that influence neuroligin-dependent synaptic maturation and plasticity.

Prioritized from 1 SciDEX hypotheses, including: Targeted Butyrate Supplementation for Microglial Phenotype Modulation